In a study including 12 AML patients with post-transplant relapse, blockade of cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) with ipilimumab produced a response rate of 42% including complete remission in 4 patients with extramedullary leukemia. The gene discussed is CTLA4; the disease is acute myeloid leukemia.